Timeline Description

2 days prior to admission Patient had fever and general fatigue while on holiday.

Day 0 On the flight back home, he had progressive chest pain, dyspnea, and syncope.

Day 0–2 h after admission At hospital admission, elevated inflammatory markers and positive troponins were observed. Electrocardiogram showed atrial fibrillation at 160 beats/min and new onset complete right bundle branch block (RBBB).

Day 0–12 h after admission Transthoracic echocardiogram (TTE), computer tomography, and coronary angiogram were performed.

Day 2 Cardiac magnetic resonance (CMR) was performed.

Day 7 Endomyocardial biopsy showed eosinophilic myocarditis. Treatment with high-dose corticosteroids started.

Within 21 days from admission The patient was diagnosed with eosinophilic granulomatosis with polyangitis (EGPA) and was treated by high-dose corticosteroids and intravenous cyclophosphamide.

2 months after discharge Repeated TTE and CMR showed stationary results. The eosinophilic count was normal, and the patient was doing well. Treatment is planned to continue with methotrexate and prednisolone in tapering doses.

Case report of eosinophilic granulomatosis with polyangitis presenting as acute myocarditis

Marie Björkenstam1,2 | Emanuele Bobbio1,2 | Tomas Mellberg1 | Christian L. Polte2,3,4 | Niklas Bergh1,2 | Francesco Giallauria5 | Entela Bollano1,2

1Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
2Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
3Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden
4Department of Radiology, Sahlgrenska University Hospital, Gothenburg, Sweden
5Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy

Correspondence Marie Björkenstam, Department of Cardiology, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden. Email: marie.bjorkenstam@vgregion.se

Abstract
This case presents a challenging diagnosis of EGPA presenting as eosinophilic myocarditis. It is a condition that can mimic many other diseases and where prompt diagnosis and early treatment is essential for recovery. The diagnosis was made after an endomyocardial biopsy (EMB) and showed the importance of EMB in the diagnostic work-up.

KEYWORDS
cardiac magnetic resonance imaging, cardiomyopathy, case report, EGPA, endomyocardial biopsy, eosinophilic myocarditis, eosinophils, myocarditis

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Eosinophilic myocarditis (EM) is a rare form of myocardial inflammation, characterized by eosinophilic infiltration, and often accompanied by hypereosinophilia. The clinical presentation can range from paucisymptomatic to acute fulminant myocarditis (so called acute necrotizing EM) or chronic restrictive cardiomyopathy (Loeffler cardiomyopathy). Clinical diagnosis is challenging, and EM is often first discovered at postmortem examination. There are several underlying causes of EM and it has been reported in association with hypersensitivity reactions, immune-mediated disorders, such as eosinophilic granulomatosis with polyangiitis (EGPA) (formerly Churg-Strauss syndrome), undefined complex hypereosinophilic syndrome (HES) or its myeloproliferative variant, infections and cancer, although the relative proportion of these associations remains incompletely understood. Furthermore, in a relatively large number of cases, the underlying cause of EM remains unknown.

However, if diagnosed early, it can be treated with anti-inflammatory therapy and patients can make a full recovery.

Studies have reported EM seen in 0.5% of unselected autopsy series, and in more than 20% of explanted hearts from heart transplant recipients. Although only endomyocardial biopsy (EMB) allows for a definite diagnosis, it is often underused in the diagnostic work-up.

A 63-year-old Caucasian male developed a fever while on holiday in Cyprus. On the flight back home, he had an episode of progressing chest pain, shortness of breath, heart palpitations, and finally syncope. In the ambulance from the airport, a standard 12 lead electrocardiogram (ECG) showed atrial fibrillation at 160 beats/min and new onset complete right bundle branch block (RBBB). At admission to the Cardiac Care Unit (CCU), the patient was dyspneic, had chest pain, and severe hypotension (systolic blood pressure 80 mmHg). No signs of overt fluid retention were observed.

The patient had a medical history of arterial hypertension, hyperlipidemia and spinal stenosis. He was on treatment with losartan, atorvastatin, omeprazole, and naproxen. He was a former smoker with a stable social situation. No relevant family history was reported.

Laboratory data showed a white blood cell count (WBC) of 19.1×10^9/l (3.5–8.8), hemoglobin (Hb) 126 g/L (134–170), Troponin-T (TnT) 400 ng/L (<14), c-reactive protein (CRP) 76 mg/L (<5), and N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) 6440 ng/L (<400).

Transthoracic echocardiogram (TTE) performed at the first day revealed mild left ventricular hypertrophy (LVH) but normal left ventricular ejection fraction (LVEF 50%–60%) and no valve abnormalities. There was a small amount of pericardial effusion without hemodynamic significance and an elevated central venous pressure of 10 mmHg. Global longitudinal strain was not performed.

Because of chest pain, the patient's medical history, gender, and age, the first suspicion upon admission was acute coronary syndrome but the coronary angiogram showed no significant stenosis. Computed tomography of the chest was negative for pulmonary embolism.

The atrial fibrillation converted spontaneously to sinus rhythm and over the next 2 days, the patient was hemodynamically stable but continued to have intermittent chest pain, fever (38°C), and elevated TnT (ranging from 400 to 650). He was not treated with antibiotics.

Since he presented with symptoms of infection, elevated TnT, and normal coronary arteries, myocarditis was
suspected. Cardiac magnetic resonance (CMR) performed at day two showed signs of mild LVH, normal LVEF (65%), and pericardial effusion, but neither clear evidence of edema nor delayed enhancement (Figure 1). However, tissue characteristics were difficult to assess due to the patient's pericardial effusion. Consequently, CMR imaging could not confirm the presence of myocarditis, a distinct cardiomyopathy or infiltrative disease.

Further investigation of inflammatory parameters showed elevated eosinophils at $1.3 \times 10^9/l$ (0.04–0.4). The WBC had then fallen to $9.1 \times 10^9/l$ and basophils, lymphocytes, neutrophils, and monocytes were in normal range. Erythrocyte sedimentation rate (ESR) was $60$ mm/h ($<20$). Rheumatologic screening showed negative antinuclear antibodies (ANA) and antineutrophil cytoplasmic antibody (ANCA). Serum- and urine-electrophoresis were normal.

The preliminary diagnosis at this point was cardiac amyloidosis based on the presentation with conduction disturbances, history of spinal stenosis and, after further questioning, also suspicion of neuropathic symptoms. Moreover, QRS-amplitudes on ECG had decreased markedly compared with a few years earlier despite the findings of LVH on TTE and CMR (Figure 2). However, myocarditis was still a possibility as the CMR might have been false negative.

A bone scintigraphy was ordered and an endomyocardial biopsy (EMB). The result of the EMB came back showing eosinophilic myocarditis (Figure 3). The referral for scintigraphy was then retracted. New blood tests 6 days after admission revealed rising eosinophils ($4.8 \times 10^9/l$) meanwhile the CRP and TnT had normalized. In consultation with rheumatologists, the patient was started on 60 mg Prednisolone daily and eosinophilic granulomatosis with polyangitis (EGPA, formerly Churg–Strauss syndrome) was suspected. The patient was then transferred to the rheumatology department for further work-up, including a bone marrow biopsy, which was normal. He was diagnosed with EGPA with the involvement of the heart and a mononeuritis of the left arm and hand with atrophy of the thenar and hypothenar musculature. However, there was no involvement of the lungs, sinuses, or kidneys and no history of asthma typical for EGPA. Nine days after starting Prednisolone, the eosinophilic count normalized ($0.4 \times 10^9/L$). ESR was $4$ mm/h, CRP $<1$ mg/L, TnT 7.5 ng/L, and NT-pro BNP 135 ng/L. At the rheumatology ward, the patient also started treatment with intravenous cyclophosphamide and later also rituximab in addition to prednisolone, according to the current treatment guidelines for EGPA.5,6 Two months later, TTE showed neither left ventricular hypertrophy nor pericardial effusion. This was confirmed by a CMR after 6 months with no signs of edema or certain delayed enhancement. The ECG was normalized with no RBBB and normal QRS-amplitudes and width. The eosinophilic count was normal, and the patient was doing well. He received a total of nine cycles of cyclophosphamide

**FIGURE 2** ECG (limb leads) in 2016 (above) and at admission (below). Showing RBBB, atrial fibrillation and lower QRS-amplitudes.

**FIGURE 3** EMB showing inflammatory infiltrates of eosinophils (arrow)
and one with rituximab. Treatment is planned to continue with methotrexate and prednisolone in tapering doses.

3 | DISCUSSION AND CONCLUSIONS

Eosinophilic myocarditis (EM) is a broad term to describe inflammatory cardiomyopathies of various pathogeneses associated with eosinophilia. Eosinophils contain cytoplasmic granules that release cytotoxic proteins on activation from immunogenic stimuli, leading to free radical formation and subsequent apoptosis and necrosis. Two manifestations are Löeffler endocarditis and endomyocardial fibrosis. It can be associated with systemic eosinophilic syndromes such as EGPA or be drug or vaccine related. It can lead to an acute life-threatening inflammatory disease of the heart. Embolic complications are common and if the disease is left untreated the prognosis is poor. EM is probably under-diagnosed and often discovered on post-mortem examination. Uncertainty remains regarding signs and symptoms at presentation, clinical course, and outcome. The course of eosinophilic myocarditis is variable due to the heterogeneity of the disease. A systemic review by Brambatti et al. found that the disorders most frequently associated with EM are hypersensitivity and EGPA, which accounted for 34.1% and 12.8% of cases, respectively. EGPA is a rare disease with a prevalence of 11–13 cases/million inhabitants, and a reported annual incidence from 0.5 to 6.8 new cases/million inhabitants. It is characterized by small- and medium-sized-vessel vasculitis and often distinguishes itself from other small-vessel vasculitis by the presence of severe asthma and blood and tissue eosinophilia. However, our patient did not have asthma and ANCA was negative. It has been shown that these patients present more frequently with cardiomyopathies, in different reports the frequency of cardiac involvement in EGPA ranges from 15% to 56%. Hypereosinophilic syndrome (HES) is a differential diagnosis, and this was also considered in our patient as the syndrome may also present with neuropathy and cardiomyopathy. However, HES patients rarely exhibit mononeuritis simplex, and the diagnosis of EGPA was established by the rheumatologists in consultation with hematologists. In this case, a number of other diagnoses were considered before EM; pulmonary embolism (dyspnea, new onset RBBB, hypotension), acute coronary syndrome (elevated TnT, new onset RBBB), myocarditis (elevated CRP, fever, small pericardial effusion), and amyloidosis (history of spinal stenosis, LV hypertrophy, smaller R-waves than previously on ECG).

Parasitic infections were never considered in this case but should have been a part of the diagnostic work-up since they are an important cause of eosinophilia. Since peripheral eosinophilia is absent in up to 25% of patients with EM, EMB plays a pivotal role in diagnosing EM. It is also important to know that eosinophilia may be absent at admission and develop later. In our case, the eosinophilic count was elevated at the time of the first blood test but rose further a few days later. According to a joint scientific statement from the American heart association/American college of cardiology and the European society of cardiology, performing EMB is reasonable in the setting of unexplained heart failure associated with dilated cardiomyopathy (DCM) of any duration that is associated with eosinophilia. Our patient did not have echocardiographic findings consistent with DCM and the case shows that EMB may be beneficial also in cases with eosinophilia without DCM. In this case, the use of EMB was pivotal. Many other diagnoses were considered and ruled out before the final diagnosis was established by EMB. A correct diagnosis allowed for successful immune modulating treatment whereas undiagnosed the prognosis is very poor. Since EGPA is a recurrent disease monitoring remission and relapse is important; however, this is difficult since there is currently no reliable biomarker to measure EGPA activity. The total eosinophil count is considered the most valuable. The definition of EGPA remission is the absence of clinical systemic manifestations and it is of importance that patients undergo lifelong monitoring and clinical evaluation.

AUTHOR CONTRIBUTIONS

Marie Björkenstam was the principal author responsible for writing the case report. Emanuele Bobbio, Entela Bollano, Christian Polte, Niklas Bergh, and Francesco Giallauria involved in co-writing and approval of final version of case report. Tomas Mellberg involved in contact with patient and co-writing and approval of final version of case report.

ACKNOWLEDGMENTS

None.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

CONSENT

Written informed consent for publication of their clinical detail and/or clinical images was obtained from the patient.
REFERENCES

1. Brambatti M, Matassini MV, Adler ED, Klingel K, Camici PG, Ammirati E. Eosinophilic myocarditis: characteristics, treatment, and outcomes. J Am Coll Cardiol. 2017;70(19):2363-2375.
2. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779-792.
3. Ginsberg F, Parrillo JE. Eosinophilic myocarditis. Heart Fail Clin. 2005;1(3):419-429.
4. Al Ali AM, Straatman LP, Allard MF, Ignaszewski AP. Eosinophilic myocarditis: case series and review of literature. Can J Cardiol. 2006;22(14):1233-1237.
5. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-1100.
6. Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48:49:99-103.
7. Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121(7):803-818.
8. Caffo AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636-2648.
9. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the heart failure Association of the European Society of cardiology. Eur Heart J. 2007;28(24):3076-3093.
10. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545-553.
11. Grayson PC, Monach PA, Pagnoux C, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(8):1351-1359.

How to cite this article: Björkenstam M, Bobbio E, Mellberg T, et al. Case report of eosinophilic granulomatosis with polyangiitis presenting as acute myocarditis. Clin Case Rep. 2022;10:e06446. doi: 10.1002/ccr3.6446